694495-63-1

Basic information

• Product Name: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE
• Synonyms: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE;N-(4-METHYL-3-PYRIDINYL)-CARBAMIC ACID, METHYL ESTER;Methyl N-(4-methylpyridin-3-yl)carbamate;CarbaMic acid, N-(4-Methyl-3-pyridinyl)-, Methyl ester;Methyl (4-Methylpyridin-3-yl)carbaMate;Carbamic acid, (4-methyl-3-pyridinyl)-, methyl ester;Tofacitinib Impurity 52;Methyl (4-methyl-3-pyridinyl)carbamate
• CAS NO: 694495-63-1
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.1772
• Mol File: 694495-63-1.mol
• Article Data: 9

Chemical Properties

• Melting Point: 117～118℃
• Boiling Point: 227.812°C at 760 mmHg
• Flash Point: 91.578°C
• Appearance: /
• Density: 1.201g/cm³
• Vapor Pressure: 0.076mmHg at 25°C
• Refractive Index: 1.567
• PKA: 12.94±0.70(Predicted)
• CAS DataBase Reference: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE(694495-63-1)
• EPA Substance Registry System: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE(694495-63-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 694495-63-1(Hazardous Substances Data)

Usage

Description

3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE, also known as Methyl 4-Methylpyridin-3-ylcarbamate, is a chemical compound with the molecular formula C7H8N2O2. It is characterized by the presence of a methylpyridine ring with a carbamate functional group attached to the 3-position. 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE has potential applications in the pharmaceutical industry due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE is used as a JAK3 inhibitor for its immunosuppressant properties. It plays a crucial role in modulating the immune response by targeting the Janus kinase 3 (JAK3) enzyme, which is involved in the signaling pathways of various cytokines and growth factors. Inhibition of JAK3 can help in the treatment of autoimmune diseases and transplant rejection by reducing inflammation and immune cell activation.

InChI:InChI=1/C8H10N2O2/c1-6-3-4-9-5-7(6)10-8(11)12-2/h3-5H,1-2H3,(H,10,11)

Upstream product

• 3430-27-1 3-amino-4-methylpyridine 
• 616-38-6 carbonic acid dimethyl ester 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1204176-45-3 cis-(4-methyl-piperidin-3-yl)-carbamic acid methyl ester 
• 1204176-45-3 trans-(4-methyl-piperidin-3-yl)-carbamic acid methyl ester 
• 923036-27-5 1-benzyl-3-methoxycarbonylamino-4-methyl-pyridinium bromide 
• 923036-29-7 1-benzyl-3-methoxycarbonylamino-4-methylpyridinium chloride 
• 1354621-59-2 cis-1-benzyl-N,4-dimethylpiperidin-3-amine 
• 1206824-67-0 methyl (1-benzyl-4-methylpiperidin-3-yl)carbamate hydrochloride 
• 1269823-99-5 4-((1-benzyl-4-methylpiperidin-3-yl)(methyl)amino)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one 
• 1204176-45-3 3-methoxycarbonylamino-4-methylpiperidine 
• 1204176-45-3 cis-3-methoxycarbonylamino-4-methylpiperidine 
• 1354621-59-2 cis-N-benzyl-3-methoxycarbonylamino-4-methylpiperidine 
• 1228879-37-5 cis-N-benzyl-3-methoxycarbonylamino-4-methylpiperidine bis(hydrochloride) 
• 1616760-91-8 methyl-(1-trityl-4-methylpiperidin-3-yl)carbamate 
• 1616833-40-9 1-triryI-N,4-dimethylpiperidin-3-amine 
• 1616761-04-6 (3S,4S)-1-trityl-N,4-dimethylpiperidin-3-amine di-p-toluyl-L-tartaric acid salt 

Relevant articles and documents

A synthetic cis - 1 - benzyl - 3 - methylamino - 4 - methyl - piperidine

The invention relates to a method for synthesizing cis-1-benzyl-3-methylamino-4-methyl-piperidine, in particular to a method for synthesizing cis-1-benzyl-3-methylamino-4-methyl-piperidine by taking 1-benzyl-3-methylamino-4-methyl-piperidine bromide as an

THE PRESENT INVENTION RELATES TO PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF.

The present invention relates to process for the preparation of tofacitinib and intermediates thereof.

HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS

The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula (I).